The MBS landscape is undergoing a paradigm shift. Optimal obesity management is evolving beyond rigid anatomical algorithms towards precision medicine, driven by the synergistic integration of dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists, procedure personalisation based on metabolic phenotyping and robust lifelong surveillance registries tailored to regional demographics.
Dholakia et al. (Mon,) studied this question.